Pulmonary Fibrosis Plasma
Pulmonary Fibrosis Plasma is collected from IRB-consented donors with clinically confirmed fibrotic lung disease. Suitable for analysing circulating cytokines, chemokines and biomarkers of extracellular matrix turnover, including TIMPs, MMPs and pro-collagen peptides. Available stratified by idiopathic versus other cause, antifibrotic treatment status and severity, with matched healthy controls.
Pulmonary Fibrosis Plasma for Fibrotic Lung Disease Research
Pulmonary Fibrosis Plasma is collected from IRB-consented donors clinically diagnosed with pulmonary fibrosis and processed within one day of collection to preserve cytokines, proteins and metabolites. Plasma is acellular, so this product is intended for soluble-analyte measurement rather than cell-based assays.
Fibrosis Biology and Why Plasma
Pulmonary fibrosis is a disorder of aberrant wound healing in the lung, not an autoimmune disease. Repeated or unresolved alveolar epithelial injury triggers a repair response that fails to switch off.
- Injured alveolar epithelium releases profibrotic mediators, with TGF-beta signalling the most consistently implicated driver of the fibrotic programme
- Resident fibroblasts differentiate into contractile, matrix-secreting myofibroblasts that persist rather than undergoing normal clearance
- Excess and abnormally cross-linked extracellular matrix accumulates, stiffening the interstitium and progressively destroying gas-exchange units
- Because matrix is constantly being synthesised and degraded, fragments of collagen, MMPs and their TIMP inhibitors enter the circulation and can be quantified in plasma
- Epithelial injury markers and mucin-associated proteins are also measurable in plasma, supporting non-invasive progression research without repeat lung biopsy
- Interstitial lung disease associated with connective tissue disease has a distinct immunological component; where relevant, we offer that as a separate stratification option rather than treating fibrosis itself as autoimmune
Donor Stratification Available
- Idiopathic pulmonary fibrosis versus fibrosis of known or other cause
- Connective-tissue-disease-associated interstitial lung disease as a separate cohort where documented
- Antifibrotic treatment status: on nintedanib, on pirfenidone, or treatment-naive
- Disease severity by pulmonary function testing where available
- Supplemental oxygen requirement
- Smoking history
- Matched healthy controls available
Product Features
- Research Use Only (RUO)
- Plasma collected from clinically confirmed Pulmonary Fibrosis donors
- Processed within one day of collection
- IRB-approved protocols and informed consent
- Custom aliquot volumes available upon request
- Anticoagulant selection available on request to match your assay
De-identified Donor Data
- Verified Pulmonary Fibrosis diagnosis
- Demographic data: age, sex assigned at birth, race/ethnicity
- Donor-reported medications, allergies, and comorbidities
- Smoking and occupational exposure history where recorded
- Additional pulmonary fibrosis-specific metadata available
Applications
- Extracellular matrix turnover biomarker measurement, including MMPs, TIMPs and pro-collagen peptides
- Epithelial injury marker profiling
- Profibrotic cytokine and chemokine quantification
- Plasma proteomics for progression and prognostic signature discovery
- Untargeted metabolomics in fibrotic lung disease
- Antifibrotic therapy response and pharmacodynamic marker research
- Non-invasive diagnostic and progression assay development
- Case-control comparisons against matched healthy donors
Other Pulmonary Fibrosis Specimen Types
- Pulmonary Fibrosis Serum
- Pulmonary Fibrosis Whole Blood
- Pulmonary Fibrosis PBMC
- Idiopathic Pulmonary Fibrosis Plasma
- Interstitial Lung Disease Whole Blood
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11 – compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Pulmonary Fibrosis plasma is available in standard and custom volumes. For pricing, availability, international orders, or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To browse plasma from other disease states and check live stock status, visit our human plasma page.
Protocols & Documentation
-
Download
Plasma Isolation
Protocol for plasma separation from anticoagulated whole blood, including processing, storage, and traceability requirements.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Plasma
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Plasma cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.